Healthcare
HHS announces AI and computational-model initiatives for clinical trials
The US Department of Health and Human Services announced plans to use AI and computational models to accelerate clinical trials and reduce rigid separation between trial phases.
The US Department of Health and Human Services announced initiatives intended to speed clinical trials by incorporating more artificial intelligence and computational models. The approach seeks to move away from sharply separated trial phases.
The initiative reflects an effort to use computational methods throughout clinical development, potentially supporting trial design, analysis and decision-making. The available report does not specify the individual models, products or disease programs involved.
The change is relevant to pharmaceutical companies and researchers because clinical trials are expensive, time-consuming and operationally complex. Computational tools can help organize evidence and inform development decisions, but they still require validation and regulatory oversight.
The announcement matters because it places AI within the US clinical-trial system rather than limiting it to laboratory discovery. A more integrated model could affect how sponsors plan and execute studies, although the cited source does not report completed trials or measured improvements.
Original source: KFF Health News